Illegally trafficked exotic snake as a reservoir for the novel carbapenem-resistant and hypervirulent Pseudomonas aeruginosa ST4309 Authors: Guilherme E. Paiva, Fábio Parra Sellera, João Pedro Rueda Furlan, Thais Martins-Gonçalves, Laura Reisfeld, Paloma Canedo, Johana Becerra, Herrison Fontana, Nilton Lincopan Published: 2026 Dear Editor, Illegal wildlife trade is a transnational crime with severe ecological and public health consequences, such as the spread of emerging pathogens and the introduction of invasive species into new geographic areas [1]. From a One Health perspective, another concern is the dissemination of critical antimicrobial-resistant bacteria. In this regard, multidrug-resistant Enterobacterales have been isolated from illegally traded wild birds and pets in Brazil, underscoring the immediate public health risks linked to these illicit supply chains [1]. Pseudomonas aeruginosa is an opportunistic pathogen responsible for diverse infections in humans and animals. The global dissemination of carbapenem-resistant P. aeruginosa has led the World Health Organization (WHO) to classify this species as a high-priority pathogen (https://www.who.int/publications/i/item/9789240093461), while the convergence of carbapenem resistance and virulence determinants further increases its clinical and public health relevance. In 2023, during an antimicrobial resistance (AMR) surveillance study in captive wildlife, in the state of São Paulo, Brazil, samples (rectal, cloacal and feces) from 35 different animals (mammals and reptiles) were screened for resistance to broad-spectrum cephalosporins and/or carbapenems by using MacConkey agar plates supplemented with 4 mg/L ceftriaxone or 2 mg/L meropenem [2]. In this regard, a carbapenem-resistant lactose-negative bacterium (named AQSP9M) was isolated from the feces collected from a python snake (Python reticulatus) rescued from illegal wildlife trafficking. This bacterial strain was identified as P. aeruginosa by MALDI-TOF MS (Bruker, Germany), displaying resistance to carbapenems (meropenem and imipenem MICs = 8 mg/L) and piperacillin/tazobactam; remaining susceptible to ticarcillin/clavulanic acid, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, cefepime, cefiderocol, aztreonam, tobramycin, amikacin, ciprofloxacin, and levofloxacin (https://www.eucast.org/). Genomic DNA extraction was carried out using the PureLink Genomic DNA kit (Thermo Fisher Scientific, USA). Whole-genome sequencing was performed on the NextSeq 500 platform (Illumina Inc., USA) after library preparation with the Nextera DNA Flex Library Preparation Kit (Illumina Inc., UK). The generated reads were de novo assembled by Unicycler v0.5.1 (https://github.com/rrwick/Unicycler), and the quality was checked using CheckM v1.2.5 (https://github.com/ecogenomics/checkm). Genomic analyses were performed using The Comprehensive Antibiotic Resistance Database (https://card.mcmaster.ca/), PubMLST (https://pubmlst.org/organisms/pseudomonas-aeruginosa), PASt v1.0 (https://cge.food.dtu.dk/services/PAst/), and Virulence Factor Database (https://www.mgc.ac.cn/VFs/). Mutations in MexAB-OprM regulators and OprD were investigated using the P. aeruginosa strain PAO1 (GenBank accession number: AE004091) as reference. The carbapenem-resistant P. aeruginosa strain AQSP9M belonged to sequence type (ST) ST4309 and serogroup O5. Although, this clone has not yet been reported in the scientific literature, during the writing of this report, we noted that a P. aeruginosa strain belonging to ST4309 from a blood sample, has been submitted to the PubMLST database, from France, in 2022 (https://pubmlst.org/bigsdb?page=info&db=pubmlst_paeruginosa_isolates&id=8668). In fact, analysis of 46,491 P. aeruginosa genomes, publicly available in the NCBI Genome database, revealed that none belonged to ST4309, indicating that AQSP9M (JBYVFX010000000) represents the first publicly available complete genome reported for this clone. Resistome analysis identified intrinsic antimicrobial resistance genes, including blaOXA-494, blaPDC-630, aph(3′)-IIb, catB7, and fosA, as well as mutations in MexR (V126E) and NalC (G71E and S209R). Moreover, the OprD outer membrane porin (the primary channel for carbapenem antibiotics) sequence contained several amino acid substitutions and three in-frame codon deletions resulting in the loss of residues S373, G383, and W417, supporting the imipenem and meropenem resistance profiles [3]. Virulence profiling revealed an extensive virulome, including the genes encoding exotoxins ExoS and ToxA. In the Galleria mellonella infection model, the strain AQSP9M (exoS+/exoU−) displayed a hypervirulent phenotype comparable to the reference strain PA14 (exoS−/exoU+), causing 100% larval mortality within approximately 19 h, whereas PA14 achieved complete lethality in 18 h (Fig. 1). This finding challenges the notion that ExoU is the primary determinant of severe virulence in P. aeruginosa [4]. Although exoU-positive strains from phylogroup B are traditionally associated with worse clinical outcomes, the marked pathogenicity of AQSP9M demonstrates that an exoS+/exoU− genetic background can also drive acute host toxicity in phylogroup A. The combined action of ExoS, ToxA, and other type III secretion system-associated factors likely contribute to this hypervirulent phenotype, as both toxins play central roles in pathogenesis and systemic host damage [4].Fig. 1Kaplan-Meier survival curves of G. mellonella infected with ∼10 CFU/larva of P. aeruginosa strain PA14 (blue), P. aeruginosa strain AQSP9M belonging to the novel ST4309 (green), and PBS control group (orange). Larvae were incubated at 37 °C and mortality was recorded hourly. Virulome analysis of P. aeruginosa strain AQSP9M predicted genes encoding alginate (alg 44, alg 8, algABCDEFGIJKLPRQUWXZ, mucABCDEP), lipopolysaccharide (waaACFGP, wzy, wzz), flagellum (flag, fleNQRS, flgABCDEFGHIJKLMN, flhABF, fliACDEFGHIJKLMNOPRS, motABCDY), type IV pili (chpABCDE, fimTUV, pilBEFGHIJKMNOPQRSTUVWX, pilY12, xcpA/pilD), type II secretion system (xcpPQRSTUVWXYZ), type III secretion system (exsABCDE, pcr 1234, pcrDGHRV, popBDN, pscBCDEFGHIJKLNOPQRSTU, exoS, exoT), type VI secretion system (clpV1, dotU1, hcp 1, hsiA1B1C1E1F1G1H1J1, vipAB, icmF1/tssM1, lip 1, ppA, tagF/ppB, tagQ, tagRST, tse 123, vgrG1ab), exotoxin A (toxA), pyoverdine (mbtH-like, ptxR, pvcABCDFGHLMNOPQS), pyochelin (fptA, pchABCDFGHIR), elastases and proteases (aprA, lasAB), phospholipase C (plcH), quorum sensing (lasI, rhlI), phenazines and pyocyanin (phzA1B1C1D1E1F1G1HMS), and rhamnolipids (rhlABC). Kaplan-Meier survival curves of G. mellonella infected with ∼10 CFU/larva of P. aeruginosa strain PA14 (blue), P. aeruginosa strain AQSP9M belonging to the novel ST4309 (green), and PBS control group (orange). Larvae were incubated at 37 °C and mortality was recorded hourly. Virulome analysis of P. aeruginosa strain AQSP9M predicted genes encoding alginate (alg 44, alg 8, algABCDEFGIJKLPRQUWXZ, mucABCDEP), lipopolysaccharide (waaACFGP, wzy, wzz), flagellum (flag, fleNQRS, flgABCDEFGHIJKLMN, flhABF, fliACDEFGHIJKLMNOPRS, motABCDY), type IV pili (chpABCDE, fimTUV, pilBEFGHIJKMNOPQRSTUVWX, pilY12, xcpA/pilD), type II secretion system (xcpPQRSTUVWXYZ), type III secretion system (exsABCDE, pcr 1234, pcrDGHRV, popBDN, pscBCDEFGHIJKLNOPQRSTU, exoS, exoT), type VI secretion system (clpV1, dotU1, hcp 1, hsiA1B1C1E1F1G1H1J1, vipAB, icmF1/tssM1, lip 1, ppA, tagF/ppB, tagQ, tagRST, tse 123, vgrG1ab), exotoxin A (toxA), pyoverdine (mbtH-like, ptxR, pvcABCDFGHLMNOPQS), pyochelin (fptA, pchABCDFGHIR), elastases and proteases (aprA, lasAB), phospholipase C (plcH), quorum sensing (lasI, rhlI), phenazines and pyocyanin (phzA1B1C1D1E1F1G1HMS), and rhamnolipids (rhlABC). Noteworthy, the reticulated python is not native to Brazil and is naturally distributed throughout South and Southeast Asia. Widely traded in the exotic pet market and frequently linked to illegal wildlife trade, this species may pose ecological and sanitary risks when introduced outside its native range, as demonstrated by the invasive Burmese python (Python bivittatus) in the Florida Everglades [5]. Accordingly, illegal trafficking and captive maintenance of exotic reptiles may facilitate the movement of global priority bacteria across geographic regions. The identification of the first genomic representative of P. aeruginosa ST4309, exhibiting carbapenem resistance and hypervirulent traits, expands our current understanding of the diversity, pathogenic potential, and ecological distribution of this clinically important species. CRediT authorship contribution statement Guilherme E. Paiva: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Conceptualization. Fábio Parra Sellera: Writing – review & editing, Writing – original draft, Visualization, Validation, Investigation, Formal analysis. João Pedro Rueda Furlan: Writing – review & editing, Writing – original draft, Validation, Investigation, Data curation. Thais Martins-Gonçalves: Writing – review & editing, Writing – original draft, Investigation, Formal analysis. Laura Reisfeld: Writing – review & editing, Writing – original draft, Visualization, Investigation. Paloma Canedo: Writing – review & editing, Writing – original draft, Visualization, Investigation. Johana Becerra: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis. Herrison Fontana: Writing – review & editing, Writing – original draft, Validation, Methodology, Formal analysis, Data curation. Nilton Lincopan: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Funding acquisition, Formal analysis, Conceptualization. Nucleotide sequence accession numbers Nucleotide sequences of P. aeruginosa AQSP9M have been deposited at GenBank® under accession number JBYVFX010000000. Ethical approval Not required. Funding statement We extend our gratitude to the Fundação de Amparo à Pesquisa do Estado de São Paulo (10.13039/501100001807FAPESP) for their support through the awarded grant (Process CEPID ARIES No. 21/10599-3). Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.